Skip to content

News

Palliative Care Consultation Improves Symptoms in Gynecolog...

Palliative Care Consultation Improves Symptoms in Gynecologic Cancer Patients

A new study published in Gynecologic Oncology found that palliative care consultation is associated with improvement in symptom burden, the majority of which occurs within one day of consultation. Palliative care (or treatment) relieves symptoms such as pain, and reduces the suffering caused by cancer. Its main purpose is to keep the best quality of life … Continued

Research

Amrita Singh Capsule Collection for Ovarian Cancer Research...

Amrita Singh Capsule Collection for Ovarian Cancer Research Fund

Starting the new year with a mission to fund ovarian cancer research Friday, January 2nd, 2015 – New York, NY Amrita Singh Jewelry is proud to announce a new initiative for the new year – a special capsule collection with a percentage of sales going to Ovarian Cancer Research Fund. Nearly 200,000 women in the … Continued

Community

FDA Approves Olaparib for Ovarian Cancer

FDA Approves Olaparib for Ovarian Cancer

(December 19, 2014) The U.S. Food and Drug Administration (FDA) has approved AstraZeneca’s Olaparib (Lynparza) for advanced, BRCA-mutated ovarian cancer, the first approval of a drug in the PARP (poly ADP-ribose polymerase) inhibitor class. The FDA also approved Myriad Genetics’ BRACAnalysis CDx test to determine patients’ BRCA status as a companion diagnostic for determining whether … Continued

Research

Partner Member Profile: Ovarian Cancer 101

Partner Member Profile: Ovarian Cancer 101

When Diane Riche’s mother was diagnosed with ovarian cancer in 2010, Diane turned to the internet for information. Through her research she came to the Alliance’s website, where she learned that ovarian cancer does in fact have symptoms. Diane recalls thinking: “What do you mean ‘Know the symptoms’? There are no symptoms for ovarian cancer!” … Continued

Community

Under the Microscope: OCRF’s 2014 Research Progress R...

Under the Microscope: OCRF’s 2014 Research Progress Report

(12/14/14) | In 2014, with your generous support OCRF grantees made significant advances in the fight against ovarian cancer, including: Thank you for supporting our mission to fund scientific research that will lead to more effective identification, treatment, and ultimately a cure for this terrible disease.

OCRA News

OCRF Research Shows Targeting microRNA May Benefit Some Ova...

OCRF Research Shows Targeting microRNA May Benefit Some Ovarian Cancer Patients

(December 10, 2014) OCRF Ann Schreiber Mentored Investigator Award Grantee, Pradeep Chaluvally-Raghavan, Ph.D., and other researchers at The University of Texas MD Anderson Cancer Center believe they may have found a molecule-based approach to halting the destructive nature of a genetic misfire called the 3q26.2 amplicon.  The research was funded in part by a grant … Continued

OCRA News

Population Screening for BRCA Mutations in Ashkenazi Jewish...

Population Screening for BRCA Mutations in Ashkenazi Jewish Women is Cost-Effective

Population-based testing for BRCA 1/2 gene mutations detects the high proportion of carriers not identified by cancer family history (FH)-based testing. A new study published in the Journal of the National Cancer Institute compared the cost-effectiveness of population-based BRCA testing with the standard FH-based approach in Ashkenazi Jewish (AJ) women. The study found that population-based … Continued

Research

Partner Member Profile: Ovarian Cancer Alliance of California

Partner Member Profile: Ovarian Cancer Alliance of California

One of the Ovarian Cancer National Alliance’s first Partner Members, the Ovarian Cancer Alliance of California (OCA) parallels the Alliance in many ways. Originally founded in 1998 as a chapter of the National Ovarian Cancer Coalition, the OCA quickly evolved as an organization, focusing more on involvement specifically in the Central Valley area, as Maria … Continued

Community

Ovarian Cancer Research Fund Legends Gala

Ovarian Cancer Research Fund Legends Gala

OCRF’s 20th Anniversary Legends Gala, hosted by Harry Connick, Jr., was held on Wednesday,  November 5th at The Pierre Hotel in New York City. Honorees included the Janet Burros Memorial Foundation, Chris Salgardo, President of Kiehl’s Since 1851, and Pierce Brosnan. The event also included tributes to the late Liz Tilberis, former OCRF President and … Continued

Events

FDA Approves Genentech's Avastin Plus Chemotherapy to ...

FDA Approves Genentech's Avastin Plus Chemotherapy to Treat Women With Platinum-Resistant Recurrent Ovarian Cancer

Genentech, a member of the Roche Group today announced that the U.S. Food and Drug Administration (FDA) approved Avastin® (bevacizumab) in combination with chemotherapy for the treatment of women with platinum-resistant, recurrent ovarian cancer. The approval was based on results from a study that showed Avastin plus chemotherapy reduced the risk of disease worsening or … Continued

Research

Bevacizumab Plus Fosbretabulin Improves Progression-Free Su...

Bevacizumab Plus Fosbretabulin Improves Progression-Free Survival in Ovarian Cancer Patients

The combination of the antiangiogenesis drug bevacizumab and the vascular-disrupting agent fosbretabulin is superior to bevacizumab alone in the treatment of recurrent ovarian, tubal, and peritoneal cancer, according to an oral presentation made at the biennial meeting of the International Gynecologic Cancer Society. A study found significant improvement in progression-free survival among patients treated with … Continued

Research

Stay Informed

Get email updates about research news, action alerts, and ways to join the fight.

We care about your data. Read our privacy policy.